Inositol 1,4,5-trisphosphate in blood and skeletal muscle in human malignant hyperthermia

British Journal of Anaesthesia

Volumn 78, Issue 5, 1997, Pages 541-547

  Wappler, F ^a   Scholz, J ^a   Kochling A ^a   Steinfath, M ^a   Krause, T ^a   Schulte Am Esch, J ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Anaesthetics volatile, halothane; Malignant hyperthermia; Metabolism, inositol phosphate; Muscle skeletal; Screening

Indexed keywords

INOSITOL 1,4,5 TRISPHOSPHATE; INOSITOL PHOSPHATE;

ADOLESCENT; ADULT; ARTICLE; BLOOD; CLINICAL ARTICLE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC PROCEDURE; DISEASE PREDISPOSITION; HUMAN; HUMAN TISSUE; MALIGNANT HYPERTHERMIA; MUSCLE BIOPSY; PRIORITY JOURNAL; RADIOIMMUNOASSAY; RELIABILITY; SCHOOL CHILD; SCREENING; SKELETAL MUSCLE;

EID: 0031011142     PISSN: 00070912     EISSN: None     Source Type: Journal    
DOI: 10.1093/bja/78.5.541     Document Type: Article

References (47)

1. The European Malignant Hyperpyrexia Group. A protocol for the investigation of malignant hyperpyrexia (MH) susceptibility. British Journal of Anaesthesia 1984; 56: 1267-1269.
2. Larach MG for the North American Malignant Hyperthermia Group. Standardization of the caffeine halothane contracture test. Anesthesia and Analgesia 1989; 69: 511-515.
3. Kalow W, Britt BA, Terreau ME, Haist C. Metabolic error of muscle metabolism after recovery from malignant hyperthermia. Lancet 1970; 2: 895-898.
4. Ellis FR, Harriman DGF, Keaney NP, Kyei-Mensah K, Tyrrell JH. Halothane induced muscle contracture as cause of hyperpyrexia. British Journal of Anaesthesia 1971; 43: 721-722.
5. 2+ release from sarcoplasmic reticulum of malignant hyperthermia susceptible pigs. Biochimica et Biophysica Acta 1991; 1064: 175-183.
6. MacLennan DH, Phillips MS. Malignant hyperthermia. Science 1992; 256: 789-794.
7. 32P-inositol-1,4,5-trisphosphate in hepatocytes and neutrophils. Nature (London) 1986; 319: 514-516.
8. Fill M, Coronado R, Mickelson JR, Vilven J, Ma J, Jacobson BA, Louis CF. Abnormal ryanodine receptor channels in malignant hyperthermia. Biophysical Journal 1990; 50: 471-475.
9. Fujii J, Otsu K, Zorzato F, DeLeon S, Khanna VK, Weiler JE, O'Brien PJ, MacLennan DH. Identification of a mutation in porcine ryanodine receptor associated with malignant hyperthermia. Science 1991; 253: 448-51.
10. Fletcher JE, Tripolitis L, Hubert M, Vita GM, Levitt RC, Rosenberg H. Genotype and phenotype relationships for mutations in the ryanodine receptor in patients referred for diagnosis of malignant hyperthermia. British Journal of Anaesthesia 1995; 75: 307-310.
11. Foster PS, Gesini E, Claudianos C, Hopkinson KC, Denborough MA. Inositol 1,4,5-trisphosphate phosphatase deficiency and malignant hyperpyrexia in swine. Lancet 1989; ii: 124-127.
12. Scholz J, Troll U, Schulte am Esch J, Hartung E, Patten M, Sandig P, Schmitz W. Inositol-1,4,5-triphosphate and malignant hyperthermia. Lancet 1991; 337: 1361.
13. Fletcher JE, Tripolitis L, Erwin K, Hanson S, Rosenberg H, Conti PA, Beech J. Fatty acids modulate calcium-induced calcium release from skeletal muscle heavy sarcoplasmic reticulum fractions: Implications for malignant hyperthermia. Biochemistry and Cellular Biology 1990; 68: 1195-1201.
14. Berridge MJ. Inositol trisphosphate and calcium signalling. Nature (London) 1993; 361: 315-325.
15. Lopez JR, Perez C, Linares N, Allen P, Terzic A. Hypersensitive response of malignant hyperthermia-susceptible skeletal muscle to inositol 1,4,5-trisphosphate induced release of calcium. Naunyn-Schmiedeberg's Archives of Pharmacology 1995; 352: 442-446.
16. 2-adrenoceptors in skeletal and cardiac muscle. Acta Anaesthesiologica Scandinavica 1993; 37: 575-583.
17. 3) in malignant hyperthermia. Medical Hypotheses 1993; 42: 190-192.
18. Tonner PH, Scholz J, Richter A, Löscher W, Steinfath M, Wappler F, Wlaz P, Hadji B, Roewer N, Schulte am Esch J. Alterations of inositol polyphosphates in skeletal muscle during porcine malignant hyperthermia. British Journal of Anaesthesia 1995; 75: 467-471.
19. 2+ signalling of skeletal muscle cells. International Journal of Biochemistry 1994; 26: 449-468.
20. Wappler F, Roewer N, Köchling A, Scholz J, Steinfath M, Schulte am Esch J. In vitro diagnosis of malignant hyperthermia susceptibility with ryanodine-induced contractures in human skeletal muscles. Anesthesia and Analgesia 1996; 82: 1230-1236.
21. Zbinden AM, Frei FJ, Funk B, Thomsen DA, Westenskow D. Determination of the partial pressure of halothane (or isoflurane) in blood. British Journal of Anaesthesia 1985; 57: 796-802.
22. Larach MG. Should we use muscle biopsy to diagnose malignant hyperthermia susceptibility? Anesthesiology 1993; 79: 1-4.
23. Larach MG, Landis JR, Bunn JS, Diaz M. Prediction of malignant hyperthermia susceptibility in low-risk subjects. Anesthesiology 1992; 76: 16-27.
24. Isaacs H, Badenhorst M. False-negative results with the muscle caffeine halothane contracture testing for malignant hyperthermia. Anesthesiology 1993; 79: 5-9.
25. Wedel DJ, Nelson TE. Malignant hyperthermia-diagnostic dilemma: false-negative contracture responses with halothane and caffeine alone. Anesthesia and Analgesia 1994; 78: 787-792.
26. Wedel DJ. The effect of age on the development of MH in susceptible piglets. Anesthesiology 1994; 81: A426.
27. Lehmann-Horn F, Iaizzo PA. Are myotonias and periodic paralyses associated with susceptibility to malignant hyperthermia? British Journal of Anaesthesia 1990; 65: 692-697.
28. Ørding H, for the European Malignant Hyperthermia Group. Experience with the European protocol for contracture testing. Journal of Neurological Sciences 1990; 98S: 522.
29. Hopkins PM, Ellis FR, Halsall PJ. Ryanodine contracture: a potentially specific in vitro diagnostic test for malignant hyperthermia. British Journal of Anaesthesia 1991; 66: 611-613.
30. Lenzen C, Roewer N, Wappler F, Scholz J, Kahl J, Blank M, Rumberger E, Schulte am Esch J. Accelerated contractures after administration of ryanodine to skeletal muscle of malignant hyperthermia susceptible patients. British Journal of Anaesthesia 1993; 71: 242-246.
31. Wappler F, Roewer N, Lenzen C, Köchling A, Scholz J, Steinfath M, Schulte am Esch J. High-purity ryanodine and 9,21-dehydroryanodine for in vitro diagnosis of malignant hyperthermia in man. British Journal of Anaesthesia 1994; 72: 240-242.
32. Hartung E, Koob M, Anetseder M, Schoemig P, Krauspe R, Hogrefe G, Engelhardt W. Malignant hyperthermia (MH) diagnostics: a comparison between the halothane-caffeine- and ryanodine-contracture-test results in MH susceptible, normal and control muscle. Acta Anaesthesiologica Scandinavica 1996; 40: 437-444.
33. Hopkins PM, Ellis FR, Halsall PJ. Comparison of in vitro contracture testing with ryanodine, halothane and caffeine in malignant hyperthermia and other neuromuscular disorders. British Journal of Anaesthesia 1993; 70: 397-401.
34. MacLennan DH, Duff C, Zorzato F, Fujii J, Philipps MS, Komeluk RG, Frodis W, Britt BA, Worton RG. Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermia. Nature (London) 1990; 343: 559-561.
35. McCarthy TV, Healy JMS, Heffron JA, Lehane M, Deufel T, Lehmann-Horn F, Farrall M, Johnson K. Localisation of the malignant hyperthermia susceptibility locus to human chromosome 19q 12-13.2. Nature (London) 1990; 343: 562-564.
36. Gillard EF, Otsu K, Fujii J, DeLeon S, Khanna VK, De Leon S, Derdemezi J, Britt BA, Duff CL, Worton RG, MacLennan DH. A substitution of cysteine for arginine 614 in the ryanodine receptor is potentially causative of human malignant hyperthermia. Genomics 1991; 11: 751-755.
37. Steinfath M, Singh S, Scholz J, Becker K, Lenzen C, Wappler F, Köchling A, Roewer N, Schulte am Esch. C1840-T mutation in the human skeletal muscle ryanodine receptor gene: frequency in northern German families susceptible to in vitro contracture response. Journal of Molecular Medicine 1995; 73: 35-40.
38. Steinfath M, Scholz J, Singh S, Wappler F. Welche Bedeutung haben Genotypveränderungen in der Diagnostik der malignen Hyperthermie? Anästhesiologie, Intensivmedizin, Notfallmedizin, Schmerztherapie 1996; 31: 1-10.
39. Levitt RC, Noun N, Jedlicka AE, McKusick VA, Marks AR, Shutack JG, Fletcher JE, Rosenberg H, Meyers DA. Evidence for genetic heterogeneity in malignant hyperthermia susceptibility. Genomics 1991; 11: 543-547.
40. Levitt RC, Olckers A, Meyers S, Fletcher JE, Rosenberg H, Isaacs H, Meyers DA. Evidence for the localization of a malignant hyperthermia susceptibility locus (MHS2) to human chromosome 17q. Genomics 1992; 14: 562-566.
41. 2/δ-subunits of the L-type voltage-dependent calcium channel to chromosome 7q and analysis of the segregation of flanking markers in malignant hyperthermia susceptible families. Human Molecular Genetics 1994; 3: 969-975.
42. Sudbrak R, Procaccio V, Klausniter M, Curran JL, Monsieurs K, Van Broeckhoven C, Ellis FR, Heytens L, Hartung EJ, Kozak-Ribbens G, Heilinger D, Weissenbach J, Lehmann-Horn F, Mueller CR, Deufel T, Stewart AD, Lunardi J. Mapping of a further malignant hyperthermia susceptibility locus to chromosome 3q13.1. American Journal of Human Genetics 1995; 56: 684-691.
43. Meyer T, Stryer L. Transient calcium release induced by successive increments of inositol 1,4,5-trisphosphate. Proceedings of the National Academy of Sciences USA 1990; 87: 3841-3845.
44. Klip A, Britt BA, Elliott ME, Walker D, Ramlal T, Pegg W. Changes in cytoplasmic free calcium caused by halothane. Role of the plasma membrane and intracellular Ca stores. Biochemistry and Cellular Biology 1986; 64: 1181-1189.
45. Klip A, Britt BA, Elliott ME, Pegg W, Frodis W, Scott E. Anaesthetic-induced increase in ionised calcium in blood mononuclear cells from malignant hyperthermia patients. Lancet 1987; ii: 463-466.
46. Ørding H. Diagnosis of susceptibility to malignant hyperthermia in man. British Journal of Anaesthesia 1988; 60: 287-302.
47. Foster PS, Gesini E, Denborough MA. Inositol 1,4,5-trisphosphate metabolism in red blood cells from individuals susceptible to malignant hyperthermia. Lancet 1993; 342: 986-987.